Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial

Biliary tract cancers (BTCs) are a difficult-to-treat group of tumors with an overall poor prognosis. Until 2022, combination chemotherapy was the first-line treatment standard for patients with advanced BTCs, achieving a moderate patient survival improvement. The evolution of chemoimmunotherapy has...

Full description

Saved in:

Bibliographic Details
Main Author:	Ralph Fritsch
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2024-10-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/HBT.OH.2024.21.157
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails
by: Jiashou Wang, et al.
Published: (2025-06-01)

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer
by: Yuefeng Hu, et al.
Published: (2025-12-01)

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population
by: Florian Gerhardt, et al.
Published: (2025-06-01)

Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India
by: Vamshi Krishna Muddu, et al.
Published: (2024-12-01)

Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis
by: Bi-Cheng Wang, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers
by: Can Jiang, et al.
Published: (2025-04-01)

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
by: Yoon-Koo Kang, et al.
Published: (2025-03-01)

Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma
by: Junying Wang, et al.
Published: (2025-06-01)

Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”
by: Chenglong Wang, et al.
Published: (2025-04-01)

Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States
by: Caicong You, et al.
Published: (2025-07-01)

Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab
by: Satoshi Mii, et al.
Published: (2025-07-01)

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial
by: Jingjing Li, et al.
Published: (2025-07-01)

Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”
by: Yoon-Koo Kang, et al.
Published: (2025-05-01)

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial
by: Xiao Yang, et al.
Published: (2025-08-01)

First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
by: Ling Fang, et al.
Published: (2023-12-01)

Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer
by: Yuxuan Xie, et al.
Published: (2025-08-01)

Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer
by: Huikai Li, et al.
Published: (2025-02-01)

Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment
by: Shiyun Cui, et al.
Published: (2025-04-01)

Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy
by: A. Lamarca, et al.
Published: (2025-03-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Biliary tract cancers: advances in diagnostic and management
by: James Gutmans, et al.
Published: (2025-06-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
by: Mayur Patel, et al.
Published: (2025-05-01)

Treatment Outcomes in Advanced Biliary Tract Cancers: Single Institution Retrospective Analysis
by: Nikhil Pathi, et al.
Published: (2025-08-01)

Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2025-05-01)

Contemporary Tailored Oncology Treatment of Biliary Tract Cancers
by: Fiona Turkes, et al.
Published: (2019-01-01)

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
by: Alfredo S. Golemba, MD, et al.
Published: (2025-05-01)

Special Criticality Safety Analysis for TOPAZ-Ⅱ Space Reactor
by: XIAO Qidong, YANG Lijun, ZHANG Pengzhan, LIU Kaikai, LIU Yang, LIU Donghai, LYU Zheng
Published: (2024-12-01)

T‐Cadherin in Biliary Tract Cancer Stroma, a Potent Pharmacological Target for Biliary Tract Carcinogenesis
by: Yuki Hanamatsu, et al.
Published: (2025-04-01)

Adjuvant chemotherapy compared with observation in patients with resected biliary tract cancer: A systematic review and meta-analysis of randomized controlled trials.
by: Liying Tian, et al.
Published: (2025-01-01)

Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin
by: Hyunho Kim, et al.
Published: (2025-08-01)

Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer
by: I. S. Krysanov, et al.
Published: (2023-11-01)

A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab
by: Makoto Sugimori, et al.
Published: (2024-11-01)

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
by: Tetsu Tomonari, et al.
Published: (2024-10-01)

Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers State of the Art and Future Directions
by: Dilara Akhoundova, et al.
Published: (2020-10-01)

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
by: Eisuke Mochizuki, et al.
Published: (2025-01-01)

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction
by: Shunsuke Imamura, et al.
Published: (2025-04-01)

Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives
by: Marco Imperatori, et al.
Published: (2016-01-01)

Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
by: Toshihiko Matsumoto, et al.
Published: (2025-08-01)

Pregnancy and the Biliary Tract
by: Tuvia Gilat, et al.
Published: (2000-01-01)